DK2488205T3 - Rekombinant humant CC10-protein til behandling af influenza - Google Patents

Rekombinant humant CC10-protein til behandling af influenza Download PDF

Info

Publication number
DK2488205T3
DK2488205T3 DK10824032.6T DK10824032T DK2488205T3 DK 2488205 T3 DK2488205 T3 DK 2488205T3 DK 10824032 T DK10824032 T DK 10824032T DK 2488205 T3 DK2488205 T3 DK 2488205T3
Authority
DK
Denmark
Prior art keywords
human uteroglobin
influenza
infection
recombinant human
viral
Prior art date
Application number
DK10824032.6T
Other languages
English (en)
Inventor
Aprile L Pilon
Pierre Borgeat Ph D
Louis Flamand Ph D
Original Assignee
Therabron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabron Therapeutics Inc filed Critical Therabron Therapeutics Inc
Application granted granted Critical
Publication of DK2488205T3 publication Critical patent/DK2488205T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (9)

1. Human uteroglobin eller rekombinant human uteroglobin til anvendelse i en behandingsfremgangsmåde til at reducere titeren af influenzavirus i lungevævet hos en patient.
2. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 1, hvor den humane uteroglobin eller rekombinante humane uteroglobin behandler, kurerer, eller forebygger en influenzainfektion hos patienten.
3. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 1, hvor influenzaen er Type A-influenza.
4. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 1, hvor influenzaen er HINl-stammen af influenza.
5. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 1, hvor den humane uteroglobin eller rekombinante humane uteroglobin indgives via den intranasale vej, den intravenøse vej eller en kombination af intranasale og intravenøse veje.
6. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 1, hvor den humane uteroglobin eller rekombinante humane uteroglobin inhiberer virusreplikation på celleniveau.
7. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 6, hvor den humane uteroglobin eller rekombinante humane uteroglobin indgives til en inficeret patient.
8. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 6, hvor den humane uteroglobin eller rekombinante humane uteroglobin indgives til et inficeret dyr.
9. Human uteroglobin eller rekombinant human uteroglobin til anvendelse ifølge krav 6, hvor den humane uteroglobin eller rekombinante humane uteroglobin indgives til en inficeret celle.
DK10824032.6T 2009-10-15 2010-10-13 Rekombinant humant CC10-protein til behandling af influenza DK2488205T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25202809P 2009-10-15 2009-10-15
PCT/US2010/052527 WO2011047065A1 (en) 2009-10-15 2010-10-13 Recombinant human cc10 protein for treatment of influenza

Publications (1)

Publication Number Publication Date
DK2488205T3 true DK2488205T3 (da) 2017-01-16

Family

ID=43876512

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10824032.6T DK2488205T3 (da) 2009-10-15 2010-10-13 Rekombinant humant CC10-protein til behandling af influenza

Country Status (18)

Country Link
US (1) US8957018B2 (da)
EP (1) EP2488205B1 (da)
JP (2) JP5944316B2 (da)
KR (1) KR101597391B1 (da)
CN (1) CN102834115B (da)
AU (1) AU2010306840B2 (da)
BR (1) BR112012008463A2 (da)
CA (1) CA2813740C (da)
DK (1) DK2488205T3 (da)
ES (1) ES2606541T3 (da)
HU (1) HUE030838T2 (da)
IL (2) IL219009A0 (da)
MX (1) MX2012004409A (da)
NZ (1) NZ599511A (da)
PL (1) PL2488205T3 (da)
PT (1) PT2488205T (da)
RU (1) RU2554745C2 (da)
WO (1) WO2011047065A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
CN102834115B (zh) * 2009-10-15 2015-01-14 克拉莱森公司 用于治疗流感的重组人cc10蛋白
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
US20140274915A1 (en) 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
US9394349B2 (en) * 2013-03-15 2016-07-19 Therabron Therapeutics, Inc. Modification and compositions of human secretoglobin proteins
AU2019387570A1 (en) * 2018-11-30 2021-07-15 Apc Research Assets Llc Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins
WO2021247756A1 (en) * 2020-06-02 2021-12-09 Apc Research Assets Llc Recombinant human cc10 protein for treatment of influenza, ebola, and coronavirus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4691009A (en) 1984-12-26 1987-09-01 Repligen Corporation Hybrid proteins produced by an ultrahigh prokaryotic expression system
US4917826A (en) 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US4820514A (en) 1985-12-30 1989-04-11 Texas A&M University System Low dosage of interferon to enhance vaccine efficiency
JP2656944B2 (ja) 1987-04-30 1997-09-24 クーパー ラボラトリーズ タンパク質性治療剤のエアロゾール化
US5266562A (en) 1987-11-19 1993-11-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-inflammatory agents
US5354269A (en) 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5482930A (en) 1993-06-09 1996-01-09 The Regents Of The University Of California Anti-inflammatory composition and method with des-Tyr dynorphin and analogues
US5470885A (en) 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
FR2724665B1 (fr) 1994-09-16 1996-12-20 Rhone Poulenc Rorer Sa Procede de production de proteines recombinantes, plasmides et cellules modifiees
US5935860A (en) 1995-03-07 1999-08-10 The George Washington University Use of uteroglobin expression as a molecular marker for prostatic intraepithelial neoplasia
US5696092A (en) 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers
WO1997001627A1 (en) 1995-06-27 1997-01-16 Igen International, Inc. High-level expression and efficient recovery of ubiquitin fusion proteins from escherichia coli
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
WO1997034997A1 (en) 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
AU5253998A (en) * 1996-11-13 1998-06-03 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20020160948A1 (en) 1998-07-21 2002-10-31 Aprile Pilon Recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030207795A1 (en) 1997-05-28 2003-11-06 Pilon Aprile L. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US7122344B2 (en) 1997-05-28 2006-10-17 Claragen, Inc. Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions
US20050261180A1 (en) 1997-05-28 2005-11-24 Pilon Aprile L Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20060025348A1 (en) 1997-05-28 2006-02-02 Pilon Aprile L Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US6255281B1 (en) 1997-05-28 2001-07-03 Claragen, Inc. And U.S. Government Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
US20020169108A1 (en) 1997-05-28 2002-11-14 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
KR20010087125A (ko) 1998-04-16 2001-09-15 데이비드 비. 맥윌리암스 인테그린 수용체에 대한 인테그린의 결합을 억제하는 화합물
WO2000072868A2 (en) * 1999-06-01 2000-12-07 Prendergast Patrick T Peptides for therapeutic use
JP2003512856A (ja) * 1999-11-04 2003-04-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ウテログロビン様ポリヌクレオチド、ポリペプチド、および抗体
AU2001253468A1 (en) 2000-04-14 2001-10-30 Claragen, Inc. Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production
AU2001282977A1 (en) 2000-07-26 2002-02-05 The Burnham Institute Screening methods based on superactivated alphavbeta3 integrin
WO2003057257A1 (en) * 2002-01-02 2003-07-17 The Johns Hopkins University Cc10 inhibits th2 cytokines and eotaxins involved in allergic diseases
US20090227025A1 (en) 2003-06-06 2009-09-10 The Board Of Regents Of The University Of Texas System Ex vivo human lung/immune system model using tissue engineering for studying microbial pathogens with lung tropism
AU2009233906A1 (en) 2008-04-08 2009-10-15 Amyris, Inc. Expression of heterologous sequences
NZ588895A (en) 2008-05-13 2012-07-27 Clarassance Inc Recombinant human CC10 (rhCC10 aka uteroglobin) and compositions thereof for use in the treatment of nasal rhinitis
CN102834115B (zh) 2009-10-15 2015-01-14 克拉莱森公司 用于治疗流感的重组人cc10蛋白

Also Published As

Publication number Publication date
CN102834115A (zh) 2012-12-19
US20120231997A1 (en) 2012-09-13
CA2813740A1 (en) 2011-04-21
WO2011047065A1 (en) 2011-04-21
RU2012120671A (ru) 2013-11-20
EP2488205B1 (en) 2016-09-21
JP5944316B2 (ja) 2016-07-05
ES2606541T3 (es) 2017-03-24
NZ599511A (en) 2014-06-27
CA2813740C (en) 2016-08-02
JP2013508283A (ja) 2013-03-07
PL2488205T3 (pl) 2018-01-31
JP2016155799A (ja) 2016-09-01
RU2554745C2 (ru) 2015-06-27
KR101597391B1 (ko) 2016-02-24
US8957018B2 (en) 2015-02-17
KR20120098699A (ko) 2012-09-05
PT2488205T (pt) 2016-11-10
EP2488205A1 (en) 2012-08-22
IL243697A0 (en) 2016-04-21
CN102834115B (zh) 2015-01-14
AU2010306840A1 (en) 2012-05-17
AU2010306840B2 (en) 2015-06-25
BR112012008463A2 (pt) 2019-09-24
IL219009A0 (en) 2012-06-28
HUE030838T2 (en) 2017-06-28
MX2012004409A (es) 2012-08-23
EP2488205A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
DK2488205T3 (da) Rekombinant humant CC10-protein til behandling af influenza
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
JPH06507404A (ja) 感染性の呼吸性疾患の治療方法
Li et al. Intranasal co-administration of 1, 8-cineole with influenza vaccine provide cross-protection against influenza virus infection
Liao et al. Ribavirin attenuates the respiratory immune responses to influenza viral infection in mice
Rennie et al. Low pH gel intranasal sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection
US20230241163A1 (en) Recombinant Human CC10 Protein for Treatment of Influenza, Ebola and Coronavirus
US9168285B2 (en) Recombinant human CC10 protein for treatment of influenza and ebola
Zhao et al. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F (ab′) 2 against highly pathogenic avian influenza H5N1 in mice
Berry et al. Passive Broad‐Spectrum Influenza Immunoprophylaxis
WO2018209447A1 (en) Method of treating respiratory tract infection
WO2016133560A1 (en) Recombinant human cc10 protein for treatment of influenza and ebola
Zhao et al. Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F (ab′) 2
US20240108713A1 (en) Novel replication deficient influenza a virus inducing high levels of type i interferon
EP4251200B1 (en) Novel replication deficient influenza a virus inducing high levels of type i interferon
Downey Mechanisms of host defense to influenza virus infection
US20080233105A1 (en) Compositions and methods for preventing or treating a viral infection
CN118434435A (zh) 用于治疗病毒感染的药物组合物
WO2022133455A1 (en) Diphenhydramine and lactoferrin for prevention and treatment of covid-19
WO2024096743A1 (en) Sars-cov-2 binding antibody
Ramasamy Immunity to human influenza A—An overview
WO2024163734A1 (en) Polyclonal antibodies to treat sars-cov-2
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
CN116635058A (zh) 抗病毒剂
Koday Influenza vaccines and antivirals that target the conserved hemagglutinin stem